Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Charl van Zyl | President & CEO | 36.9M | -- | 1967 |
| Mr. Joerg Hornstein | CFO & Executive VP of Corporate Functions | 8.5M | -- | 1977 |
| Mr. Lars Bang | Executive Vice President of Product Development & Supply | 7.9M | -- | 1962 |
| Dr. Tarek Samad Ph.D. | Senior VP & Head of Research | -- | -- | -- |
| Mr. Palle Holm Olesen | Chief Specialist & VP of Investor Relations | -- | -- | -- |
| Ms. Tine Ostergaard Hansen | Senior Vice President of Corporate Communications & Public Affairs | -- | -- | 1975 |
| Ms. Dianne Holto | Executive Vice President of People & Culture | -- | -- | 1973 |
| Mr. Ole Chrintz | Senior Vice President of International Markets | -- | -- | 1958 |
| Dr. Rupert Sandbrink M.D., Ph.D. | Senior VP & Head of Clinical Development | -- | -- | 1964 |
| Mr. Bjorn R. Mogensen | Senior Vice President of Group Finance | -- | -- | -- |
H. Lundbeck A/S
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 5,800
Description
H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat MDD and schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat dementia; Onfi for epilepsy; Sabril for the treatment of refractory complex partial seizures and infantile spasms; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol to treat psychosis. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.
Corporate Governance
Upcoming Events
February 5, 2025 at 7:30 AM UTC
H. Lundbeck A/S Earnings Date
Recent Events
March 21, 2024 at 12:00 AM UTC
Ex-Dividend Date